Forte Biosciences posts Q3 net loss of $17.7 million

Reuters11-14

Forte Biosciences posts Q3 net loss of $17.7 million

Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114817278) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583501214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583501214","market":"nz","top_or_hot":-1,"title":"Forte Biosciences posts Q3 net loss of $17.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Forte Biosciences posts Q3 net loss of $17.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114817278) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences posts Q3 net loss of $17.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences posts Q3 net loss of $17.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Forte Biosciences posts Q3 net loss of $17.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114817278) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBRX","symbol_name":"Forte BioSciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL5fk3qt:1","article_id":"2583501214","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583501214","pubTimestamp":1763128842,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FBRX":"Forte BioSciences Inc","BK4139":"生物科技"},"translate_title":"Forte Biosciences第三季度净亏损1770万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9},"content_text":"Forte Biosciences posts Q3 net loss of $17.7 million\n    \n\n        Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114817278) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583501214","isCrawlerRequest":true}